-- 根据西太平洋银行和墨尔本研究所周三发布的一份报告,澳大利亚经济活动指标3月份出现下滑,表明由于利率上升和消费者信心疲软,经济增长预期再次放缓,前景承压。 西太平洋银行-墨尔本研究所领先指数(Westpac-Melbourne Institute Leading Index)显示,未来三到九个月经济活动相对于趋势的可能增速,该指数从2月份的0.05%降至3月份的-0.13%。 西太平洋银行澳大利亚宏观预测主管马修·哈桑表示,澳大利亚经济在2026年初出现放缓,3月份的指数表明,自去年以来,经济增长首次低于趋势水平,这可能标志着继2022年至2024年受生活成本上涨影响的疲软期之后,又一个经济低迷期的开始。 领先指数显著走弱,从去年10月的0.31%涨幅转为目前的0.15%跌幅,主要受利率上升和中东紧张局势引发的能源市场新压力影响。 哈桑表示,澳大利亚整体增长势头受到消费者信心疲软、3月份股市大幅抛售以及收益率差收窄的拖累,但如果4月初股市反弹能够持续,则可能预示着短期内经济将有所缓解。 大宗商品价格和波动较大的住宅审批是近期指数上涨的主要驱动因素,而其他成分股自去年10月以来合计没有对指数做出净贡献。 哈桑补充道,由于潜在通胀上升和通胀预期走高的风险超过了经济增长放缓的迹象(尽管这些迹象仍然温和),预计澳大利亚储备银行货币政策委员会将在5月份的会议上再次加息25个基点。
Related Articles
National Australia Bank Shares Down After Resolution of Union Court Proceedings
National Australia Bank (ASX:NAB) shares were down about 1% in recent Monday trade following a Friday settlement with the Finance Sector Union of Australia to resolve court proceedings related to excessive additional working hours for employees.The settlement, reached on a without-admissions basis through mediation, includes the establishment of a health, safety, and well-being framework to mitigate the risks linked to working additional hours, and calls for greater oversight of such risks.The union and the bank said in a joint statement that they are "committed to continuing to work together to ensure fair and sustainable outcomes for all [National Australia Bank] employees."
Clinuvel Pharmaceuticals Says FDA Removes Post-Authorization Requirement for Implant
Clinuvel Pharmaceuticals (ASX:CUV) said the US Food and Drug Administration (FDA) removed a requirement for a post-authorization phase one study on cardiac repolarization in relation to its Scenesse implant upon reviewing its long-term safety profile, according to a Monday filing with the Australian bourse.Scenesse is used to treat patients with erythropoietic protoporphyria, a disease that causes intolerance to light.The FDA concluded that the study was no longer needed since it would not yield valuable safety information, the filing said.
XRF Scientific Completes Acquisition of Combustion Gas Analysis Business
XRF Scientific (ASX:XRF) has completed the acquisition of the combustion gas analysis business from Bruker AXS, according to a Monday Australian bourse filing.The company entered a binding agreement to acquire the combustion gas analysis business for $4 million upfront plus a potential $1 million earnout based on 7% of net revenue over three years, an earlier filing showed.